Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for bladder cancer patients: radiotherapy trial aims to improve survival and quality of life

NCT ID NCT07524426

Disease control Sponsor: Umeå University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase III trial tests whether adding local radiotherapy to standard care helps bladder cancer patients who are not eligible for curative treatment live longer and feel better. About 248 participants will be randomly assigned to receive either standard care alone or standard care plus modern, targeted radiotherapy. The study also collects biomarkers to personalize future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Local hypofractionated adaptive radiotherapy
What this could lead to
If successful, this could offer a well-tolerated treatment option that extends survival and improves quality of life for bladder cancer patients who cannot have curative therapy.
What could go wrong
This is an early-stage trial with 248 participants, so results may not apply to all patients. Radiotherapy can cause side effects like bladder irritation or fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 248 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2034

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Oral and written consent 2. Histologically confirmed MIBC with urothelial component 3. Male or female participants ≥ 18 years old 4. Deemed not to benefit from curative treatment at a multidisciplinary tumour conference (MDT) or having declined curative treatment of their own accord. Exclusion Criteria: 1. Clinical Fragility Scale score ≥8 2. Previous pelvic RT with significant overlap 3. Visceral or bone metastases on CT scan 4. Multiple (\>3) lymph node metastases with a measurement of \>2 cm on CT scan 5. Planed for systemic treatment at the time of inclusion. 6. Local RT to the bladder indicated for the palliation of symptoms at the time of inclusion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bladder cancer (BC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bladder cancer (BC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Norrlands University Hosital

    RECRUITING

    Umeå, Västerbotten County, 90185, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.